EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prevalence of Actionable Pharmacogenetic Genotype Frequencies, Cautionary Medication Use, and Polypharmacy in Community‐Dwelling Older Adults

Prävalenz verwertbarer pharmakogenetischer Genotypen, vorsichtiger Medikation und Polypharmazie bei älteren Menschen in der Gemeinde

Chad A Bousman iD, Ankita Narang iD, Ziad Al Bkhetan iD, Robyn L Woods iD, Suzanne G Orchard iD, Alice J Owen iD, Michelle A Fravel iD, Julia Gilmartin-Thomas iD, Joanne Ryan iD, Peter D Fransquet iD, Rory Wolfe iD, Chenglong Yu iD und 3 weitere

Clinical Pharmacology & Therapeutics · 2025-08 · 118 (2) · 337-342

DOI: 10.1002/cpt.3702 ↗

Auf einen Blick

Bei 13.670 älteren Erwachsenen aus der ASPREE-Studie waren verwertbare pharmakogenetische Genotypen, Polypharmazie und CYP-Inhibitoren/-Induktoren häufig. 98,8 % trugen mindestens einen verwertbaren Genotyp.

Fragestellung

Wie häufig treten verwertbare pharmakogenetische Genotypen, vorsichtige Medikation, Polypharmazie und CYP-Inhibitoren/-Induktoren bei älteren Erwachsenen in der Gemeinde auf?

Methode

Analyse von 13.670 älteren Erwachsenen aus der ASPREE-Studie; Genotypisierung von 10 Pharmakogenen mit PGx-Leitlinien; jährliche Medikationsdaten zur Erfassung vorsichtiger Medikation und CYP-Inhibitoren/-Induktoren.

Ergebnisse

98,8 % hatten mindestens einen verwertbaren PGx-Genotyp; im Mittel drei pro Person. VKORC1: 61,1 %, CYP2C19: 59,6 %. 27,5 % nahmen mindestens ein Medikament mit abweichender PGx-Empfehlung; 83,9 % Polypharmazie; 68,2 % CYP-Inhibitoren/-Induktoren.

Schlussfolgerung der Autor:innen

Die Autor:innen berichten eine hohe Prävalenz verwertbarer PGx-Genotypen, Polypharmazie sowie von Inhibitoren und Induktoren bei älteren Erwachsenen.

Kernaussagen

  • 98,8 % mit mindestens einem verwertbaren PGx-Genotyp
  • 27,5 % mit mindestens einem Medikament mit PGx-Abweichung
  • 83,9 % mit Polypharmazie; 68,2 % mit CYP-Inhibitoren/-Induktoren

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 30.04.2025. Verfasst von Chad A Bousman und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Genetics, Physiology & Pharmacology, and Psychiatry, University of Calgary, Calgary, Alberta, Canada. Hauptthemen laut MEDLINE: Polypharmacy, Pharmacogenetics, Drug-Related Side Effects and Adverse Reactions, Pharmacogenomic Variants. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NHMRC, National Institute on Aging and the National Cancer Institute at the National Institutes of Health.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Older adults (65 years and over) frequently manage complex medication regimens and are vulnerable to adverse drug reactions and treatment inefficacies, some of which could be preventable with pharmacogenetics (PGx)‐guided prescribing. This study examined the prevalence of actionable PGx genotypes (i.e., those linked to a guideline that recommends a change to standard prescribing), the use of cautionary medications (i.e., those associated with an actionable PGx genotype), polypharmacy (i.e., ≥ 5 medications simultaneously), and cytochrome P450 enzyme inhibitor and inducer use among 13,670 older adults enrolled in the ASPirin in Reducing Events in the Elderly (ASPREE) trial. Genotyping was conducted for 10 pharmacogenes with actionable PGx‐based prescribing guidelines. Medication data were collected annually and assessed to identify cautionary medication use in the cohort. Most participants (98.8%) carried at least one actionable PGx genotype, with an average of three actionable genotypes per participant. VKORC1 (61.1%) and CYP2C19 (59.6%) were the most frequently observed genes with actionable genotypes. Statins (29.3%), nonsteroidal anti‐inflammatory drugs (14.2%), and proton‐pump inhibitors (7.9%) were the most used cautionary medications, with 27.5% of participants taking at least one medication for which PGx guidelines recommended a deviation from standard prescribing. Most (83.9%) participants reported taking a polypharmacy regimen, and 68.2% reported use of at least one cytochrome P450 enzyme inhibitor or inducer during the trial. Our findings underscore the high prevalence of actionable PGx genotypes, polypharmacy, and use of inhibitors and inducers in older adults, which collectively have the potential to inform safer and more effective prescribing practices.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PolypharmacyPharmacogeneticsDrug-Related Side Effects and Adverse ReactionsPharmacogenomic VariantsHumansAgedMaleFemaleAged, 80 and overIndependent LivingPrevalenceGenotypePharmacogenomic TestingGene Frequency

Autor:innen und Institutionen

  • Department of Medical Genetics, Physiology & Pharmacology, and Psychiatry, University of Calgary, Calgary, Alberta, Canada.
  • The Mathison Centre for Mental Health Research & Education, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Alberta Children's Hospital Research Institute, University of Calgary, Calgary, Alberta, Canada.
  • Australian BioCommons, The University of Melbourne, Melbourne, Victoria, Australia.
  • School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
  • Department of Pharmacy Practice and Science, College of Pharmacy, The University of Iowa, Iowa City, Iowa, USA.

ORCID-Profile: Chad A Bousman, Ankita Narang, Ziad Al Bkhetan, Robyn L Woods, Suzanne G Orchard, Alice J Owen, Michelle A Fravel, Julia Gilmartin-Thomas, Joanne Ryan, Peter D Fransquet, Rory Wolfe, Chenglong Yu, John J McNeil, Paul Lacaze, Michael E Ernst

Förderung

  • NIA NIH HHS
  • NHMRC
  • National Institute on Aging and the National Cancer Institute at the National Institutes of Health
  • National Health and Medical Research Council of Australia
  • Commonwealth Scientific and Industrial Research Organization
  • NCI NIH HHS
  • Monash University and the Victorian Cancer Agency
  • National Cancer Institute

Zitieren

APA

Bousman, C. A., Narang, A., Al Bkhetan, Z., Woods, R. L., Orchard, S. G., Owen, A. J., Fravel, M. A., Gilmartin-Thomas, J., Ryan, J., Fransquet, P. D., Wolfe, R., Yu, C., McNeil, J. J., Lacaze, P., & Ernst, M. E. (2025). Prevalence of Actionable Pharmacogenetic Genotype Frequencies, Cautionary Medication Use, and Polypharmacy in Community‐Dwelling Older Adults. Clinical Pharmacology & Therapeutics, 118(2), 337-342. https://doi.org/10.1002/cpt.3702

Vancouver

Bousman CA, Narang A, Al Bkhetan Z, Woods RL, Orchard SG, Owen AJ, et al. Prevalence of Actionable Pharmacogenetic Genotype Frequencies, Cautionary Medication Use, and Polypharmacy in Community‐Dwelling Older Adults. Clinical Pharmacology & Therapeutics. 2025;118(2):337-342. doi:10.1002/cpt.3702

BibTeX
@article{Bousman2025,
  author = {Bousman, Chad A and Narang, Ankita and Al Bkhetan, Ziad and Woods, Robyn L and Orchard, Suzanne G and Owen, Alice J and Fravel, Michelle A and Gilmartin-Thomas, Julia and Ryan, Joanne and Fransquet, Peter D and Wolfe, Rory and Yu, Chenglong and McNeil, John J and Lacaze, Paul and Ernst, Michael E},
  title = {Prevalence of Actionable Pharmacogenetic Genotype Frequencies, Cautionary Medication Use, and Polypharmacy in Community‐Dwelling Older Adults},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  volume = {118},
  number = {2},
  pages = {337--342},
  doi = {10.1002/cpt.3702}
}
Kostenlos starten →